Literature DB >> 8200564

Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2.

S Pugh1, G A Thomas.   

Abstract

Colorectal carcinoma in humans and animal models is associated with increased synthesis of prostaglandin E2 (PGE2). PGE2 synthesis was measured in normal and neoplastic human colorectal mucosa to investigate its role in the adenoma-carcinoma sequence. Paired mucosal biopsy specimens for PGE2 synthesis and histological examination were obtained during 39 diagnostic colonoscopies. Twelve control patients in whom colonoscopies and histology were normal synthesised similar amounts of PGE2 at all sites. Their results were (mean (SD) pg PGE2/mg tissue) caecum 102.8 (15.9) (n = 6), ascending colon 110.8 (24.3) (n = 10), transverse colon 103.9 (19.5) (n = 11), descending colon 102.9 (23.2) (n = 12), sigmoid colon 96.4 (18.0) (n = 12), and rectum 107.1 (17.6) (n = 12). Nineteen patients had a total of 27 adenomatous polyps (rectum (1), sigmoid (22), descending (1), transverse (1), and ascending colon (1): histology-tubular (16), tubulo-villous (8), and villous adenomous (3)). The polyps (178.0 (55.0), n = 27) synthesised more PGE2 than controls (p < 0.001), but the values in polyp-associated mucosa (mean (SD) 115.4 (21.9), n = 15) were not different to control results. Eight patients had carcinomas (rectal (2), sigmoid (4), and caecal (2)) all of which were adenocarcinomas. The cancers (193.6 (40.2), n = 8) synthesised more PGE2 than control specimens (p < 0.001), but were not different to polyps. Cancer-associated mucosa (140.3 (27.7) n = 8) synthesised more PGE2 than control and polyp-associated mucosa. Colorectal neoplasia is associated with a progressive increase in PGE2 synthesis which may have a role in tumourigenesis and be a pathophysiological explanation for the beneficial effects of NSAIDs in animal models and human disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200564      PMCID: PMC1374755          DOI: 10.1136/gut.35.5.675

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

1.  Aspirin use and reduced risk of fatal colon cancer.

Authors:  M J Thun; M M Namboodiri; C W Heath
Journal:  N Engl J Med       Date:  1991-12-05       Impact factor: 91.245

2.  Investigation of colonic prostaglandins in carcinogenesis in the rat colon.

Authors:  A Yamaguchi; T Ishida; G Nishimura; M Katoh; I Miyazaki
Journal:  Dis Colon Rectum       Date:  1991-07       Impact factor: 4.585

Review 3.  Prostaglandins and cancer: an update.

Authors:  B M Jaffe
Journal:  Prostaglandins       Date:  1974-06-25

4.  Immunochemical measurement of prostaglandin or prostaglandin-like activity from normal and neoplastic cultured tissue.

Authors:  B M Jaffe; C W Parker; G W Philpott
Journal:  Surg Forum       Date:  1971

5.  Relationship between blood plasma prostaglandin E2 and liver and lung metastases in colorectal cancer.

Authors:  T Narisawa; H Kusaka; Y Yamazaki; M Takahashi; H Koyama; K Koyama; Y Fukaura; A Wakizaka
Journal:  Dis Colon Rectum       Date:  1990-10       Impact factor: 4.585

6.  Prostaglandins from tumours of human large bowel.

Authors:  A Bennett; M D Tacca; I F Stamford; T Zebro
Journal:  Br J Cancer       Date:  1977-06       Impact factor: 7.640

7.  Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer.

Authors:  M Anti; G Marra; F Armelao; G M Bartoli; R Ficarelli; A Percesepe; I De Vitis; G Maria; L Sofo; G L Rapaccini
Journal:  Gastroenterology       Date:  1992-09       Impact factor: 22.682

8.  Immune modulatory effects of indomethacin in melanoma patients are not related to prostaglandin E2-mediated suppression.

Authors:  A B Tilden; C M Balch
Journal:  Surgery       Date:  1982-09       Impact factor: 3.982

Review 9.  Prostaglandins and cancer: a review of tumor initiation through tumor metastasis.

Authors:  K V Honn; R S Bockman; L J Marnett
Journal:  Prostaglandins       Date:  1981-05

10.  Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis.

Authors:  P A Craven; F R DeRubertis
Journal:  Carcinogenesis       Date:  1992-04       Impact factor: 4.944

View more
  71 in total

1.  Urinary prostaglandin E2 metabolite and risk for colorectal adenoma.

Authors:  Martha J Shrubsole; Qiuyin Cai; Wanqing Wen; Ginger Milne; Walter E Smalley; Zhi Chen; Reid M Ness; Wei Zheng
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-13

2.  Effect of fish oil on levels of R- and S-enantiomers of 5-, 12-, and 15-hydroxyeicosatetraenoic acids in mouse colonic mucosa.

Authors:  Andrew P Neilson; Jianwei Ren; Yu H Hong; Ananda Sen; William L Smith; Dean E Brenner; Zora Djuric
Journal:  Nutr Cancer       Date:  2011-12-09       Impact factor: 2.900

3.  Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers.

Authors:  Hui-Hua Chang; Zuohe Song; Lee Wisner; Tina Tripp; Vijay Gokhale; Emmanuelle J Meuillet
Journal:  Invest New Drugs       Date:  2011-09-20       Impact factor: 3.850

4.  Effect of cyclooxygenase genotype and dietary fish oil on colonic eicosanoids in mice.

Authors:  Andrew P Neilson; Zora Djuric; Jianwei Ren; Yu H Hong; Ananda Sen; Corey Lager; Yan Jiang; Shony Reuven; William L Smith; Dean E Brenner
Journal:  J Nutr Biochem       Date:  2011-09-19       Impact factor: 6.048

5.  Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway.

Authors:  Juanjuan Wu; Yushan Zhang; Nicole Frilot; Jae I Kim; Wan-Ju Kim; Yehia Daaka
Journal:  J Biol Chem       Date:  2011-08-10       Impact factor: 5.157

6.  Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice.

Authors:  Naoko Niho; Michihiro Mutoh; Mami Takahashi; Kazuhiko Tsutsumi; Takashi Sugimura; Keiji Wakabayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

7.  Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy.

Authors:  N Banu; A Buda; S Chell; D Elder; M Moorghen; C Paraskeva; D Qualtrough; M Pignatelli
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

8.  Bile acids inhibit NAD+-dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes.

Authors:  Akira Miyaki; Peiying Yang; Hsin-Hsiung Tai; Kotha Subbaramaiah; Andrew J Dannenberg
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-16       Impact factor: 4.052

9.  Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development.

Authors:  Y Shoji; M Takahashi; T Kitamura; K Watanabe; T Kawamori; T Maruyama; Y Sugimoto; M Negishi; S Narumiya; T Sugimura; K Wakabayashi
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 10.  Physical activity before and after diagnosis of colorectal cancer: disease risk, clinical outcomes, response pathways and biomarkers.

Authors:  David J Harriss; N Tim Cable; Keith George; Thomas Reilly; Andrew G Renehan; Najib Haboubi
Journal:  Sports Med       Date:  2007       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.